Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
BB Biotech closed its first quarter of 2016 with a loss of 1.2 billion Swiss francs while it achieved a
profit of 379 million Swiss francs in the corresponding period of the previous year. (reuters.com)
Indivior has appointed Lizabeth Zlatkus as an independent non-executive director with effect from 1
September. Zlatkus will also become a member of the audit committee. (stockmarketwire.com)
Novartis announced that its generic arm, Sandoz, has received approval from the European
Commission for a type II variation of Binocrit, a biosimilar version of Eprex. (yahoo.com)
Novo Nordisk has re ei ed the Clayto To Cou il’s lessi g to pro eed ith its $1.8 illio
expansion concerning its insulin-making plant just outside of Clayton. (newsobserver.com)
Qiagen has partnered with Mirati Therapeutics to co-develop and commercialize a companion
diagnostic for Mirati's glesatinib. (genomeweb.com)
Roche has been given a second fast-track designation for atezolizumab in patients with locally
advanced or metastatic non-small cell lung cancer. (fiercebiotech.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 7
2016-04-17
Astellas AbbVie BB Biotech Biogen Bristol-Myers Squibb Celgene CSL
Indivior Medtronic Novartis Novo Nordisk Qiagen Roche Takeda
SPOTLIGHT
COMPANY NEWS
AbbVie won U.S. regulatory approval for a new drug, venetoclax, to treat patients with a rare type of
chronic lymphocytic leukemia, a genetic mutation known as 17p gene deletion. (reuters.com)
Biogen is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic
areas and implements its restructuring program announced last October. (reuters.com)
Bristol-Myers Squibb re ei ed FDA’s appro al to expand the use of its cancer drug Opdivo to
patients who are facing difficult-to-treat variations of Hodgkin lymphoma. (wsj.com)
Celgene and Juno Therapeutics announced that Celgene exercised its option to develop and
commercialize the Juno CD19 program outside North America and China. (pharmpro.com)
Medtronic continues to invest in new businesses and participates in financing Foundry Innovation &
Research 1 (FIRE1), a company developing remote monitoring technology. (meddeviceonline.com)
Astellas has been allowed to sell parts of its dermatological products to LEO Pharma. The UK’s CMA
found the acquisition unlikely to result in a substantial lessening of competition. (lexology.com)
CSL, the Australian maker of blood-deri ed therapies, sees s art acquisitions as a way to spur
growth, though M&A activities are closely checked for their valued added to CSL. (bloomberg.com)
Takeda and Teva have officially launched their Japanese joint venture and named Hiroshi Matsumori
as its chief executive. (pmlive.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
98%
100%
102%
104%
106%
2016-04-11 2016-04-12 2016-04-13 2016-04-14 2016-04-15
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
This week’s sto k perfor a e of the world’s iggest listed health are o pa ies shows a positive
development of +2.1% while their one year change reaches -10.8%. Main driver was the Asian/Pacific
region with +5.3% on a weekly basis and +7.2% on a yearly basis. Europe increased by +1.5% whereas
North America achieved +2.0%. The respective one year performance is -14.9% and -11.1%.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 7
2016-04-17
Christian Hansen Elekta GN Store Nord Grifols Hikma
Indivior Orpea Qiagen Sanofi William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
Taki g a look at Europe’s top perfor er this week, the ost striki g a didate is Hikma, gaining
+6.1% on a weekly basis while its one year performance reaches +1.9%. Second winner from Europe
is Sanofi with a gain of +3.9% this week, whereas its one year change amounts to -21.1%.
Regarding the lower end of the weekly performance ranking, Christian Hansen takes the lead due to
its decline of -4.5% compared to its one year change of +17.7%. Next is Grifols, suffering from a
decrease of -4.1% this week and facing a one year performance of -9.7%.
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
724.98 +1.46% -14.87% 728.92 704.49 877.15 654.95
STOXX® North America 600
Health Care
813.18 +1.99% -11.06% 818.91 789.06 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
445.26 +5.26% +7.18% 445.59 418.88 446.92 349.32
STOXX® Global 1800
Health Care
719.28 +2.12% -10.81% 723.16 696.76 842.76 647.94
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Christian Hansen 56.01 -4.47% +17.71% 58.87 55.27 61.59 42.22
Grifols 19.27 -4.07% -9.68% 20.19 19.23 22.96 17.25
GN Store Nord 17.60 -2.86% -8.52% 18.01 17.45 19.92 14.72
Orpea 73.25 -2.70% +22.36% 75.24 73.25 76.72 58.21
Indivior 2.10 -2.33% -31.28% 2.16 2.00 3.89 1.61
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Hikma 2'214.00 +6.08% +1.88% 2'239.00 2'113.00 2'520.00 1'575.00
Sanofi 77.22 +3.86% -21.13% 78.19 73.30 101.00 66.50
Qiagen 20.55 +2.88% -15.19% 20.70 19.64 26.00 17.77
William Demant 91.40 +2.79% +17.23% 93.30 87.60 93.30 66.45
Elekta 6.42 +2.74% -22.98% 6.69 6.12 9.16 5.50